Physician profile
John Peter Lucia
NPI 1730175332
$720.41
in general payments reported to CMS, 2019-2025
15 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $43.29 · 2021: $19.69 · 2022: $56.11 · 2023: $147 · 2024: $102 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390 · Education: $6.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.53 |
| Education | $6.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $136.31 | 2019 | |
| Aurinia Pharma U.S., INC. | $118.13 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $90.61 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $86.06 | 2024-2025 | |
| Ardelyx, INC. | $58.31 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $35.53 | 2023-2024 | |
| Fresenius USA Marketing, INC. | $30.79 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $29.27 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.48 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.04 | 2023 | Jynarque |
| Calliditas Therapeutics US INC. | $22.96 | 2023 | Tarpeyo |
| Vantive US Healthcare LLC | $19.39 | 2025 | Renal - Pd |
| Amgen INC. | $16.45 | 2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $15.76 | 2022 | |
| Scpharmaceuticals INC. | $13.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lucia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.